Objective When developing new medicines for children, the potential to extrapolate from adult data to reduce the experimental burden in children is well recognised. However, significant assumptions about the similarity of adults and children are needed for extrapolations to be biologically plausible. We reviewed the literature to identify statistical methods that could be used to optimise extrapolations in paediatric drug development programmes. Methods Web of Science was used to identify papers proposing methods relevant for using data from a ‘source population’ to support inferences for a ‘target population’. Four key areas of methods development were targeted: paediatric clinical trials, trials extrapolating efficacy across ethnic groups...
During drug development, matching adult systemic exposures of drugs is a common approach for dose se...
BACKGROUND: Clinical trial investigators may need to evaluate treatment effects in a specific subgro...
Background: Clinical trial investigators may need to evaluate treatment effects in a specific subgr...
Objective When developing new medicines for children, the potential to extrapolate from adult data t...
When developing a new medicine for children, the potential to extrapolate from adult efficacy data i...
When developing a new drug product for children, it is important to provide safe and effective medic...
International audienceThe number of trials conducted and the number of patients per trial are typica...
Pharmacometric modelling plays a key role in both the design and analysis of regulatory trials in pa...
Children are considered a vulnerable group and as such are granted additional protection as research...
Pediatric patients should have access to medicines that have been appropriately evaluated for safety...
This thesis addresses extrapolation techniques for statistical models for dose-finding studies in pe...
Data from clinical trials in adults, extrapolated to predict benefits in paediatric patients, could ...
Aims In the EU, development of new medicines for children should follow a prospectively agreed paedi...
During drug development, matching adult systemic exposures of drugs is a common approach for dose se...
BACKGROUND: Clinical trial investigators may need to evaluate treatment effects in a specific subgro...
Background: Clinical trial investigators may need to evaluate treatment effects in a specific subgr...
Objective When developing new medicines for children, the potential to extrapolate from adult data t...
When developing a new medicine for children, the potential to extrapolate from adult efficacy data i...
When developing a new drug product for children, it is important to provide safe and effective medic...
International audienceThe number of trials conducted and the number of patients per trial are typica...
Pharmacometric modelling plays a key role in both the design and analysis of regulatory trials in pa...
Children are considered a vulnerable group and as such are granted additional protection as research...
Pediatric patients should have access to medicines that have been appropriately evaluated for safety...
This thesis addresses extrapolation techniques for statistical models for dose-finding studies in pe...
Data from clinical trials in adults, extrapolated to predict benefits in paediatric patients, could ...
Aims In the EU, development of new medicines for children should follow a prospectively agreed paedi...
During drug development, matching adult systemic exposures of drugs is a common approach for dose se...
BACKGROUND: Clinical trial investigators may need to evaluate treatment effects in a specific subgro...
Background: Clinical trial investigators may need to evaluate treatment effects in a specific subgr...